Anzeige
Mehr »
Donnerstag, 04.09.2025 - Börsentäglich über 12.000 News
Set to Action: Q-Gold vor drastischer Neubewertung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CPCZ | ISIN: US94132V1052 | Ticker-Symbol: 717
Tradegate
03.09.25 | 12:56
1,450 Euro
-5,23 % -0,080
Branche
Finanzdienstleistungen
Aktienmarkt
ASIEN
1-Jahres-Chart
WATERDROP INC ADR Chart 1 Jahr
5-Tage-Chart
WATERDROP INC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
1,5201,61020:55
1,5301,61020:19
PR Newswire
43 Leser
Artikel bewerten:
(0)

Waterdrop Inc. Announces Second Quarter 2025 Unaudited Financial Results and a Cash Dividend

BEIJING, Sept. 4, 2025 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three and six months ended June 30, 2025 and a cash dividend.

Financial and Operational Highlights for the Second Quarter of 2025

  • Further improvement in profitability: In the second quarter of 2025, net profit attributable to our ordinary shareholders reached RMB140.2 million (US$19.6 million), representing a solid increase of 58.7% year-over-year. We continued to generate positive operating cash flow during the second quarter of 2025.
  • Significant growth in insurance premiums: The first-year premiums ("FYP") generated through our insurance business reached RMB3,204.3 million (US$447.3 million) during the second quarter of 2025, representing an increase of 80.2% year-over-year. Net operating revenue was RMB838.0 million (US$117.0 million), representing an increase of 23.9% year-over-year.
  • Medical crowdfunding coverage: As of June 30, 2025, around 480 million people had cumulatively donated an aggregate of RMB70.0 billion to 3.54 million patients through Waterdrop Medical Crowdfunding.
  • Patient recruitment performance: As of June 30, 2025, the Company had cumulatively enrolled 12,216 patients into 1,385 clinical trial programs through the E-Find Platform.

Mr. Peng Shen, Founder, Chairman, and Chief Executive Officer of Waterdrop, commented, "We are proud to announce that we have delivered strong revenue and profit, fueled by the further integration of AI into our sales and service processes.

The insurance business delivered an exceptional quarter. Year-over-year, FYP grew by 95.0% in short-term policies and 45.4% in long-term ones. This robust growth drove significant increases in both segment revenue and operating profit, expanding the operating margin by 2 percentage points. These results underscore the effectiveness of our strategic focus on enhanced user acquisition, accelerated product iteration, and the implementation of AI-enhanced services.

Our "Waterdrop Guardian" AI Application Suite constantly evolves, either interacting directly with end users or empowering our online consultants behind the scenes. Premiums facilitated by 'AI Medical Insurance Expert' climbed 155% compared to the previous quarter. 'AI Customer Service Agent' resolved 60% of inquiries on first contact, enhancing user experience. 'Life Planner Copilot' has handled 300,000 insurance product-related consultations from our online consultants, driving a double-digit productivity growth in Q2. We recently launched 'KEYI.AI', a real-time AI underwriting assistant for consultants, with plans to extend its availability to industry partners later this year.

On a separate note, we completed the acquisition of the remaining equity in Shenlanbao in June and anticipate further accelerating synergies.

During the second quarter, Waterdrop Medical Crowdfunding upgraded its risk assessment capabilities. A large-language-model ("LLM") engine now scans every campaign's content, comments and hidden clues, feeding insights into a smart matrix that tracks 15 high-risk scenarios, and refines itself to identify risks more accurately. Additionally, this quarter we partnered with Guangzhou's Civil Affairs Bureau to launch 'Waterdrop Co-Help', the first project under our new designation as a government-endorsed platform that integrates social and public welfare resources.

In this quarter, E-Find Platform expanded its collaboration to 198 pharmaceutical and contract research organizations. Meanwhile, we initiated services for 114 new programs. The number of patients enrolled also reached a historic high, with 999 patients enrolled in the second quarter of 2025, representing a 34.2% year-over-year revenue growth.

With a commitment to superior shareholder returns, we are pleased to announce that our board of directors of the Company (the "Board") has recently approved an enhanced cash dividend of US$10.9 million, representing a 50% increase over the previous dividend. The Board has also authorized a fifth annual share repurchase scheme. Since the launch of our first share repurchase program in 2021, we have repurchased approximately 55.7 million ADSs for US$109.0 million as of August 31, 2025.

Looking ahead to the second half of 2025, we will strive to deliver both top-line and bottom-line growth. We believe that tech-driven innovation is the core strategy and source of business excellence, and look forward to delivering a compelling success story, as well as value to our users, partners and shareholders."

Financial Results for the Second Quarter of 2025

Operating revenue, net

Net operating revenue for the second quarter of 2025 increased by 23.9% year-over-year to RMB838.0 million (US$117.0 million) from RMB676.2 million for the same period of 2024. On a quarter-over-quarter basis, net operating revenue increased by 11.2%.

  • Insurance-related income includes insurance brokerage income and technical service income. Insurance brokerage income represents brokerage commissions earned from insurance companies. Technical service income is derived from providing technical services including risk control technical service, user analytics and intelligent recommendation service, customer relationship maintenance, customer complaint management, claim review, and user referral services, among other things, to insurance companies, insurance brokers, and agency companies. Our insurance-related income amounted to RMB738.6 million (US$103.1 million) in the second quarter of 2025, representing an increase of 28.7% year-over-year from RMB573.8 million for the second quarter of 2024, which was mainly due to the increase in technical service income. On a quarter-over-quarter basis, insurance-related income increased by 12.2%.
  • Crowdfunding service fees represent the service income earned when patients successfully withdraw the proceeds from their crowdfunding campaigns. Our role is to operate the Waterdrop Medical Crowdfunding platform to provide crowdfunding related services through the internet, enabling patients with significant medical bills to seek help from caring hearts through technology (the "medical crowdfunding services"). Our medical crowdfunding services generally consist of providing technical and internet support, managing, reviewing and supervising the crowdfunding campaigns, providing comprehensive risk management and anti- fraud measures, and facilitating the collection and transfer of the funds. For the second quarter of 2025, we generated RMB67.4 million (US$9.4 million) in service fees, representing a slight decrease of 2.7% year-over-year from RMB69.3 million for the second quarter of 2024. On a quarter-over-quarter basis, crowdfunding service fees remained stable.
  • Digital clinical trial solution income represents the service income earned from our customers mainly including biopharmaceutical companies and leading biotechnology companies. We match qualified and suitable patients for enrollment in clinical trials for our customers and generate digital clinical trial solution revenue for successful matches and we typically charge our customers a fixed unit price per successful match. For the second quarter of 2025, our digital clinical trial solution income amounted to RMB27.7 million (US$3.9 million), representing an increase of 34.2% from RMB20.7 million in the same period of 2024. On a quarter-over-quarter basis, digital clinical trial solution income increased by 20.6%.

Operating costs and expenses

Operating costs and expenses increased by 18.7% year-over-year to RMB740.6 million (US$103.4 million) for the second quarter of 2025. On a quarter-over-quarter basis, operating costs and expenses increased by 9.3%.

  • Operating costs increased by 30.5% year over year to RMB416.5 million (US$58.1 million) for the second quarter of 2025, as compared with RMB319.1 million for the second quarter of 2024, which was primarily driven by (i) an increase of RMB73.4 million in costs of referral and service fees, (ii) an increase of RMB10.8 million in the costs for the crowdfunding consultants team, and (iii) an increase of RMB7.0 million in personnel costs. On a quarter-over-quarter basis, operating costs increased by 11.3% from RMB374.2 million, primarily due to (i) an increase of RMB25.0 million in costs of referral and service fees, and (ii) an increase of RMB7.3 million in personnel costs.
  • Sales and marketing expenses increased by 26.3% year-over-year to RMB198.8 million (US$27.7 million) for the second quarter of 2025, as compared with RMB157.4 million for the same quarter of 2024. The increase was primarily due to an increase of RMB44.3 million in marketing expenses for third-party traffic channels. On a quarter-over-quarter basis, sales and marketing expenses increased by 15.3% from RMB172.4 million, primarily due to an increase of RMB25.4 million in marketing expenses for third-party traffic channels.
  • General and administrative expenses decreased by 21.9% year-over-year to RMB73.4 million (US$10.2 million) for the second quarter of 2025, compared with RMB94.0 million for the same quarter of 2024. The year-over-year variance was due to (i) a decrease of RMB13.4 million in allowance for credit losses, and (ii) a decrease of RMB6.0 million in professional service fees. On a quarter-over-quarter basis, general and administrative expenses decreased by 2.1% from RMB74.9 million, due to our effective cost control measures.
  • Research and development expenses remained stable at RMB51.9 million (US$7.3 million) for the second quarter of 2025, maintaining nearly the same level as RMB53.3 million for the same period of 2024. On a quarter-over-quarter basis, research and development expenses decreased by 7.6% from RMB56.2 million. The decrease was primarily due to a decrease of RMB3.8 million in personnel costs and share-based compensation expenses.

Operating profit for the second quarter of 2025 was RMB97.3 million (US$13.6 million), as compared with RMB52.4 million for the second quarter of 2024 and RMB75.9 million for the first quarter of 2025.

Interest income for the second quarter of 2025 was RMB29.5 million (US$4.1 million), as compared with RMB37.5 million for the second quarter of 2024 and RMB33.8 million for the first quarter of 2025, which was mainly due to the decrease of cash position.

Income tax benefit for the second quarter of 2025 was RMB2.9 million (US$0.4 million), as compared with income tax expense of RMB7.0 million for the second quarter of 2024 and RMB13.3 million for the first quarter of 2025.

Net profit attributable to the Company's ordinary shareholders for the second quarter of 2025 was RMB140.2 million (US$19.6 million), as compared with RMB88.3 million for the same period of 2024, and RMB108.2 million for the first quarter of 2025.

Adjusted net profit attributable to the Company's ordinary shareholders (non-GAAP(1)) for the second quarter of 2025 was RMB151.6 million (US$21.2 million), as compared with RMB108.7 million for the same period of 2024, and RMB130.0 million for the first quarter of 2025.

Cash position(2)

As of June 30, 2025, cash position of the Company was RMB3,406.7 million (US$475.6 million), as compared with RMB3,670.3 million as of December 31, 2024.

(1) See the sections entitled "Non-GAAP Financial Measure" and "Reconciliations of GAAP and Non-GAAP Results" for more information about the non-GAAP
measures referred to in this announcement.

(2) Cash position includes cash and cash equivalents, short-term investments, and long-term debt investments included in long-term investments.

Share Repurchase Programs

Pursuant to the share repurchase programs launched in September 2021, September 2022, September 2023 and September 2024, respectively, we had cumulatively repurchased approximately 55.7 million ADSs from the open market with cash for a total consideration of approximately US$109.0 million as of August 31, 2025.

Our Board has approved a new share repurchase program whereby the Company is authorized to repurchase its own ordinary shares in the form of American depository shares with an aggregate value of up to US$50 million during the 12-month period through September 9, 2026. The Company expects to fund the repurchase from its existing cash balance. The Company's proposed repurchases may be made from time to time in the open market at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. The timing and dollar amount of repurchase transactions will be subject to the requirements of the Securities and Exchange Commission Rule 10b-18 and/or Rule 10b5-1. The Board will review the share repurchase program periodically, and may authorize adjustment to its terms and size or suspend or discontinue the program.

Cash Dividend

The Board has approved a cash dividend of US$0.03 per ADS or US$0.003 per ordinary share, for a total amount of approximately US$10.9 million, to shareholders of record as of the close of business on October 10, 2025. The payment date is expected to be on or around November 4, 2025, for holders of ordinary shares and on or around November 7, 2025, for holders of ADSs.

Supplemental Information

We organize and report our business in the following operating segments:

  • Insurance, which mainly includes insurance brokerage service and technical service;
  • Crowdfunding, which mainly includes crowdfunding service; and
  • Others, which do not individually or in the aggregate meet the quantitative and qualitative thresholds to be individually reportable and are aggregated.

The table below sets forth the segment operating results, with three-month and six-month ended June 30, 2024 retrospectively adjusted to conform to t his presentation.



For the Three Months Ended


For the Six Months Ended



June 30, 2024


March 31, 2025


June 30, 2025


June 30, 2024


June 30, 2025



RMB


RMB


RMB


USD


RMB


RMB


USD



(All amounts in thousands)






Operating revenue, net















Insurance


573,832


657,988


738,561


103,099


1,180,609


1,396,549


194,951

Crowdfunding


69,323


67,131


67,419


9,411


136,673


134,550


18,782

Others


33,001


28,575


31,979


4,465


63,574


60,554


8,453

Total consolidated operating revenue, net


676,156


753,694


837,959


116,975


1,380,856


1,591,653


222,186

Operating costs and expenses















Insurance


(450,877)


(506,575)


(567,642)


(79,239)


(928,491)


(1,074,217)


(149,955)

Crowdfunding


(92,259)


(97,299)


(99,519)


(13,892)


(191,846)


(196,818)


(27,475)

Others


(60,451)


(54,000)


(58,620)


(8,183)


(122,456)


(112,620)


(15,721)

Operating profit/(loss)















Insurance


122,955


151,413


170,919


23,860


252,118


322,332


44,996

Crowdfunding


(22,936)


(30,168)


(32,100)


(4,481)


(55,173)


(62,268)


(8,693)

Others


(27,450)


(25,425)


(26,641)


(3,718)


(58,882)


(52,066)


(7,268)

Total segment operating profit


72,569


95,820


112,178


15,661


138,063


207,998


29,035

Unallocated items*


(20,205)


(19,927)


(14,842)


(2,072)


(39,335)


(34,769)


(4,854)

Total consolidated operating profit


52,364


75,893


97,336


13,589


98,728


173,229


24,181

Total other income


38,366


41,690


40,032


5,589


81,147


81,722


11,408

Consolidated profit before income tax


90,730


117,583


137,368


19,178


179,875


254,951


35,589
















* The share-based compensation represents unallocated items in the segment information because our management does
not consider this as part of the segment operating performance measure.

Recent Development

In order to strengthen synergies between the Group and Shenlanbao, the Group entered into a new share purchase agreement with all non-controlling shareholders of Shenlanbao to acquire all remaining equity interests in Shenlanbao. All of the closing conditions included in the new agreement had been met as of June 30, 2025, and since then, Shenlanbao has been 100% owned by the Group. The transaction was treated as an equity transaction and the difference between the consideration paid and the carrying amount of the previously recorded redeemable non-controlling interest was recognized in equity.

With full ownership, the Group can drive stronger strategic synergy. This acquisition also enables us to strengthen our service differentiation and extend technology deployment. By leveraging the Group's industry insights while preserving Shenlanbao's operational independence, we will unlock new growth opportunities for the enlarged entity.

Exchange Rate

This announcement contains translations of certain RMB amounts into U.S. dollars ("USD" or "US$") at specified rates solely for the convenience of the reader. Unless otherwise stated, all translations from RMB to USD were made at the rate of RMB7.1636 to US$1.00, the noon buying rate in effect on June 30, 2025 in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or USD amounts referred could be converted into USD or RMB, as the case may be, at any particular rate or at all. For analytical presentation, all percentages are calculated using the numbers presented in the financial statements contained in this earnings release.

Non-GAAP Financial Measure

The Company uses non-GAAP financial measure, adjusted net profit attributable to our ordinary shareholders, in evaluating the Company's operating results and for financial and operational decision-making purposes. Adjusted net profit attributable to our ordinary shareholders represents net profit attributable to our ordinary shareholders excluding share-based compensation expense attributable to our ordinary shareholders and foreign currency exchange gain or losses. Such adjustments have no impact on income tax.

The non-GAAP financial measure is not presented in accordance with U.S. GAAP and may be different from non-GAAP methods of accounting and reporting used by other companies. The non-GAAP financial measure has limitations as analytical tools and when assessing the Company's operating performance, investors should not consider it in isolation, or as a substitute for net loss or other consolidated statements of comprehensive loss data prepared in accordance with U.S. GAAP. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure. Investors are encouraged to review the Company's historical non-GAAP financial measure to the most directly comparable GAAP measure. Adjusted net profit attributable to our ordinary shareholders presented here may not be comparable to similarly titled measure presented by other companies. Other companies may calculate similarly titled measure differently, limiting its usefulness as a comparative measure to our data.

The Company mitigates these limitations by reconciling the non-GAAP financial measure to the most comparable U.S. GAAP performance measure, all of which should be considered when evaluating the Company's performance.

For more information on the non-GAAP financial measure, please see the table captioned "Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.

Safe Harbor Statement

This press release contains statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "likely to" and similar statements. Among other things, quotations in this announcement, contain forward-looking statements. Waterdrop may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Waterdrop's beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Waterdrop's mission, goals and strategies; Waterdrop's future business development, financial condition and results of operations; the expected growth of the insurance, medical crowdfunding and healthcare industry in China; Waterdrop's expectations regarding demand for and market acceptance of our products and services; Waterdrop's expectations regarding its relationships with consumers, insurance carriers and other partners; competition in the industry and relevant government policies and regulations relating to insurance, medical crowdfunding and healthcare industry. Further information regarding these and other risks is included in Waterdrop's filings with the SEC. All information provided in this press release is as of the date of this press release, and Waterdrop does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Conference Call Information

Waterdrop's management team will hold a conference call on September 4, 2025 at 8:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time on the same day) to discuss the financial results. Dial-in details for the earnings conference call are as follows:

International:

1-412-317-6061

United States Toll Free:

1-888-317-6003

Hong Kong Toll Free:

800-963976

Hong Kong:

852-58081995

Mainland China:

4001-206115

Chinese Line (Mandarin) Entry Number:

0088782

English Interpretation Line (Listen-only Mode) Entry Number:

7013962

Participants can choose between the Chinese and the English interpretation lines. Please note that the English interpretation option will be in listen-only mode. Please dial in 15 minutes before the call is scheduled to begin and provide the Elite Entry Number to join the call.

Telephone replays will be accessible two hours after the conclusion of the conference call through September 11, 2025 by dialing the following numbers:

United States Toll Free:

1-877-344-7529

International:

1-412-317-0088

Chinese Line Access Code:

4409082

English Interpretation Line Access Code:

3334217

A live and archived webcast of the conference call will also be available at the Company's investor relations website at http://ir.waterdrop-inc.com/.

About Waterdrop Inc.
Waterdrop Inc. (NYSE: WDH) is a leading technology platform dedicated to insurance and healthcare service with a positive social impact. Founded in 2016, with the comprehensive coverage of Waterdrop Insurance Marketplace and Waterdrop Medical Crowdfunding, Waterdrop aims to bring insurance and healthcare service to billions through technology. For more information, please visit www.waterdrop-inc.com.

For investor inquiries, please contact
Waterdrop Inc.
[email protected]

WATERDROP INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(All amounts in thousands, unless otherwise noted)



As of


December 31, 2024


June 30, 2025


RMB


RMB


USD

Assets






Current assets






Cash and cash equivalents

986,323


722,006


100,788

Restricted cash

520,588


637,817


89,036

Short-term investments

1,612,619


942,293


131,539

Accounts receivable, net

716,206


838,571


117,060

Current contract assets

619,436


679,254


94,820

Amount due from related parties

257


315


44

Prepaid expense and other assets

182,641


202,457


28,263

Total current assets

4,638,070


4,022,713


561,550

Non-current assets






Non-current contract assets

153,749


195,902


27,347

Property, equipment and software, net

240,024


246,610


34,425

Intangible assets, net

153,011


152,946


21,350

Long-term investments

1,114,160


1,786,589


249,398

Right of use assets, net

46,872


17,185


2,399

Deferred tax assets

27,028


20,332


2,838

Goodwill

80,751


80,751


11,272

Total non-current assets

1,815,595


2,500,315


349,029

Total assets

6,453,665


6,523,028


910,579







Liabilities, Mezzanine Equity and Shareholders'
Equity






Current liabilities






Amount due to related parties

10,616


9,834


1,373

Insurance premium payables

537,344


608,994


85,012

Accrued expenses and other current liabilities

704,035


724,189


101,093

Short-term loans

198,373


63,000


8,794

Current lease liabilities

34,573


11,866


1,656

Total current liabilities

1,484,941


1,417,883


197,928

Non-current liabilities






Non-current lease liabilities

10,971


4,948


691

Deferred tax liabilities

84,185


87,602


12,229

Total non-current liabilities

95,156


92,550


12,920

Total liabilities

1,580,097


1,510,433


210,848







Mezzanine Equity






Redeemable non-controlling interests

76,133


-


-







Shareholders' equity






Class A ordinary shares

112


114


16

Class B ordinary shares

27


27


4

Treasury stock

(15)


(15)


(2)

Additional paid-in capital

6,832,214


6,847,516


955,876

Accumulated other comprehensive income

159,550


111,052


15,502

Accumulated deficit

(2,194,453)


(1,946,099)


(271,665)

Total shareholders' equity

4,797,435


5,012,595


699,731

Total liabilities, mezzanine equity and shareholders' equity

6,453,665


6,523,028


910,579

WATERDROP INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(All amounts in thousands, except for share and per share data, or otherwise noted)




For the Three Months Ended


For the Six Months Ended



June 30, 2024


March 31, 2025


June 30, 2025


June 30, 2024


June 30, 2025



RMB


RMB


RMB


USD


RMB


RMB


USD
















Operating revenue, net


676,156


753,694


837,959


116,975


1,380,856


1,591,653


222,186

Operating costs and expenses(i)















Operating costs


(319,101)


(374,218)


(416,493)


(58,140)


(650,344)


(790,711)


(110,379)

Sales and marketing expenses


(157,413)


(172,396)


(198,785)


(27,749)


(339,559)


(371,181)


(51,815)

General and administrative expenses


(93,978)


(74,943)


(73,400)


(10,246)


(182,939)


(148,343)


(20,708)

Research and development expenses


(53,300)


(56,244)


(51,945)


(7,251)


(109,286)


(108,189)


(15,103)

Total operating costs and expenses


(623,792)


(677,801)


(740,623)


(103,386)


(1,282,128)


(1,418,424)


(198,005)

Operating profit


52,364


75,893


97,336


13,589


98,728


173,229


24,181

Other income















Interest income


37,510


33,814


29,534


4,123


77,314


63,348


8,843

Foreign currency exchange (loss)/gain


(444)


(2,103)


2,656


371


1,070


553


77

Others, net


1,300


9,979


7,842


1,095


2,763


17,821


2,488

Profit before income tax


90,730


117,583


137,368


19,178


179,875


254,951


35,589

Income tax (expense)/benefit


(7,026)


(13,328)


2,852


398


(15,614)


(10,476)


(1,462)

Net profit


83,704


104,255


140,220


19,576


164,261


244,475


34,127

Net (loss)/profit attributable to mezzanine equity classified as non-
controlling interests shareholders


(4,586)


(3,940)


61


9


(4,661)


(3,879)


(541)

Net profit attributable to ordinary shareholders


88,290


108,195


140,159


19,567


168,922


248,354


34,668

Other comprehensive income:















Foreign currency translation adjustment, net of tax


13,497


(14,056)


(33,283)


(4,646)


38,640


(47,339)


(6,608)

Unrealized gain/(loss) on available for sale investments, net of tax


-


17,612


(18,771)


(2,620)


-


(1,159)


(162)

Total comprehensive income


97,201


107,811


88,166


12,310


202,901


195,977


27,357

Total comprehensive (loss)/profit attributable to mezzanine equity
classified as non-controlling interests shareholders


(4,586)


(3,940)


61


9


(4,661)


(3,879)


(541)

Total comprehensive income attributable to ordinary shareholders


101,787


111,751


88,105


12,301


207,562


199,856


27,898

Weighted average number of ordinary shares used in computing
net profit per share















Basic


3,660,589,600


3,620,380,862


3,608,253,358


3,608,253,358


3,678,604,386


3,614,283,609


3,614,283,609

Diluted


3,734,346,444


3,711,999,000


3,711,084,352


3,711,084,352


3,745,404,276


3,711,508,175


3,711,508,175

Net profit per share attributable to ordinary shareholders















Basic


0.02


0.03


0.04


0.01


0.05


0.07


0.01

Diluted


0.02


0.03


0.04


0.01


0.05


0.07


0.01































(i) Share-based compensation expenses are included in the operating costs and expenses as follows.




























For the Three Months Ended


For the Six Months Ended



June 30, 2024


March 31, 2025


June 30, 2025


June 30, 2024


June 30, 2025



RMB


RMB


RMB


USD


RMB


RMB


USD

Sales and marketing expenses


(1,320)


(1,899)


(1,949)


(272)


(3,140)


(3,848)


(537)

General and administrative expenses


(16,285)


(15,527)


(11,899)


(1,661)


(30,612)


(27,426)


(3,829)

Research and development expenses


(2,600)


(2,501)


(994)


(139)


(5,583)


(3,495)


(488)

Total


(20,205)


(19,927)


(14,842)


(2,072)


(39,335)


(34,769)


(4,854)

WATERDROP INC.

RECONCILIATIONS OF GAAP AND NON-GAAP RESULTS

(All amounts in thousands, unless otherwise noted)

































For the Three Months Ended


For the Six Months Ended



June 30, 2024


March 31, 2025


June 30, 2025


June 30, 2024


June 30, 2025



RMB


RMB


RMB


USD


RMB


RMB


USD
















Net profit attributable to the Company's ordinary
shareholders


88,290


108,195


140,159


19,567


168,922


248,354


34,668

Add:















Share-based compensation expense attributable to the
Company's ordinary shareholders


20,015


19,750


14,144


1,974


39,274


33,894


4,731

Foreign currency exchange loss/(gain)


444


2,103


(2,656)


(371)


(1,070)


(553)


(77)

Adjusted net profit attributable to the Company's ordinary
shareholders


108,749


130,048


151,647


21,170


207,126


281,695


39,322

SOURCE Waterdrop Inc.

© 2025 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.